ClinicalTrials.gg
Not yet recruitingNCT07845955INSPIRE-T1DUpdated Sep 29, 2026

JAK1 Inhibitor Ivarmacitinib for Improving Pancreatic Islet Function in T1D

A Phase 2 interventional study of Ivarmacitinib and Placebo in T1DM - Type 1 Diabetes Mellitus, sponsored by Huijie Zhang. Not yet recruiting at 1 site in China. Open to participants aged 10 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Huijie Zhang · Phase 2, Interventional, and Treatment

Updated Sep 29, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
10 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 103 studies in Diabetes Mellitus, Type 1 with a site in China — 42 open to participants now, 45 under way, 3 of them phase 3. Diabetes Mellitus, Type 1 · China.

Planned enrollment
24th of 83
132 · median 50
Started
2026
with 5 others
Phase 2
6 of 103
2 open now
Primary completion
2029-08
later than 41 of 44 live
Registered
102nd of 103
by date

Among the 103 studies in Diabetes Mellitus, Type 1 with a site in China, this one is the 24th largest by planned enrollment of the 83 interventional ones that give a count, is one of 6 that started in 2026, is one of 6 in phase 2, reaches primary completion later than 41 of the 44 other live ones, and was the 102nd registered.

Diabetes Mellitus, Type 1

3,754 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

42 of the 103 studies in Diabetes Mellitus, Type 1 with a site in China are open now. Recruiting first, the newest first:

37 more — sign in →

All 42 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.

This study: 10 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Diabetes Mellitus, Type 1 with a site in China, or all of them as a file.
02

Study summary

This is a double-blind, randomized, placebo-parallel-controlled, multicenter study. The objective is to evaluate the efficacy and safety of Ivarmacitinib 8 mg administered for 52 weeks in preserving pancreatic β cell function in subjects with newly-onset type 1 diabetes mellitus. The study consists of a screening period (V1, up to 2 weeks), a 52-week double-blind treatment period (V2 to V14), and a 4-week safety follow-up period (V15).

03

Conditions studied

  • T1DM - Type 1 Diabetes Mellitus

Keywords

  • Type 1 Diabetes Mellitus
  • JAK1 Inhibitor
  • Ivarmacitinib
04

Who can participate

Ages eligible
10 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Confirmed diagnosis of type 1 diabetes mellitus.
  2. Able to complete randomization and initiate treatment with the study drug within 100 days of being formally diagnosed with type 1 diabetes.
  3. Peak stimulated C-peptide level ≥ 0.2 pmol/mL during the mixed-meal tolerance test performed in the screening period.
  4. Tested positive for at least one type 1 diabetes-associated autoantibody.

Exclusion criteria

Exclusion Criteria:

  1. Presence of any disease other than type 1 diabetes mellitus, except for stable autoimmune thyroid disease.
  2. Presence of active infection and/or fever.
  3. Known current or prior infection with (HIV), virus (HBV), or virus (HCV), or serological evidence of such infection at screening.
  4. Active pulmonary tuberculosis, , etc.
  5. Severe hepatic impairment ( or ALT >3 × ), or severe renal impairment or end-stage renal disease ( \< 30 mL/min/1.73 m²).
  6. Prior exposure to immunomodulatory agents, including baricitinib, ivarmacitinib, IL-1 receptor antagonists, tocilizumab (anti-IL-6 monoclonal antibody), infliximab (anti-TNF-α monoclonal antibody), interferons, etc.
  7. Severe cardiovascular disease such as angina pectoris, myocardial infarction, or stroke within the previous 6 months.
  8. Severe gastrointestinal disease.
  9. Surgical procedure performed within the past 6 months.
  10. Medical, psychological, or social conditions that, in the opinion of the investigator, may interfere with trial safety or proper completion.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
132 participants (estimated)

Study arms

  • Experimental
    Ivarmacitinib 8 mg group

    Drug: Ivarmacitinib

  • Placebo comparator
    Placebo control group

    Drug: Placebo

Interventions

  • Oral tablet, administered at a fixed dose of 8mg once daily for 52 weeks.

  • DrugPlacebo

    Oral tablet matching active Ivarmacitinib in appearance and scheduling, without active ingredients, taken once daily for 52 weeks.

06

What researchers measure

Primary outcomes

  1. Change from baseline in MMTT-stimulated C-peptide AUC at Week 52

    Change from baseline in C-peptide area under the curve (AUC) during a mixed-meal tolerance test (MMTT) after 52 weeks of treatment.

    Time frame: From Baseline to Week 52

Secondary outcomes

  1. Change from baseline in MMTT-stimulated C-peptide AUC at Week 26

    Change from baseline in C-peptide area under the curve (AUC) during a mixed-meal tolerance test (MMTT) after 26 weeks of treatment.

    Time frame: From Baseline to Week 26

  2. Change from baseline in HbA1c at Week 52

    Change from baseline in glycated hemoglobin (HbA1c) after 52 weeks of treatment.

    Time frame: From Baseline to Week 52

  3. Change from baseline in daily insulin dose at Week 52

    Change from baseline in daily insulin dose after 52 weeks of treatment

    Time frame: From Baseline to Week 52

  4. Change from baseline in TIR assessed by CGM at Week 52

    Change from baseline in time-in-range (TIR) assessed by continuous glucose monitoring (CGM) after 52 weeks of treatment.

    Time frame: From Baseline to Week 52

  5. Cumulative severe hypoglycemic events from baseline to Week 52

    Total number of severe hypoglycemic events that occurred during 52 weeks of treatment.

    Time frame: From Baseline to Week 52

  6. Change from baseline in lymphocyte subpopulation quantified by flow cytometry at week 52

    Peripheral Blood Mononuclear Cell (PBMC) will be isolated and lymphocyte subpopulation will be quantified at baseline and Week 52

    Time frame: From Baseline to Week 52

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — All IPD that underlie results in a publication.

Supporting information: Study protocol, Statistical analysis plan

Time frame: After publication.

Access criteria: IPD and supporting information will be available to researchers upon reasonable request (e.g. with a practical and meaningful research proposal).

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Aug 2029, 35 months later.

Of 83 non-industry phase 2 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 76. This study's planned 35 months is below that.

Counting every sponsor, half of 133 studies reached it within 36 months; a quarter within 17 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2026
First posted
Sep 29, 2026
StartEst.
Sep 30, 2026
Primary completionEst.
Aug 31, 2029
CompletionEst.
Dec 31, 2029
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07845955
Lead sponsor
Huijie Zhang
Responsible party
Huijie Zhang (Chief Physician, Shanghai Zhongshan Hospital) — Sponsor-investigator
First posted
Sep 29, 2026
Start date
Sep 30, 2026 (estimated)
Primary completion
Aug 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Sep 29, 2026

Study contacts

jingjing jiang, PhD
Contact
jiang.jingjing@zs-hospital.sh.cn
13402003919
Huijie Zhang
principal investigator · Fudan University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivarmacitinib

Start the discussion